Stock Analysis
- United States
- /
- Pharma
- /
- NYSE:TEVA
Teva Pharmaceutical Industries First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Teva Pharmaceutical Industries (NYSE:TEVA) First Quarter 2024 Results
Key Financial Results
- Revenue: US$3.82b (up 4.3% from 1Q 2023).
- Net loss: US$139.0m (loss narrowed by 32% from 1Q 2023).
- US$0.12 loss per share (improved from US$0.18 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Teva Pharmaceutical Industries Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates by 149%.
Looking ahead, revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are up 13% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of Teva Pharmaceutical Industries' balance sheet and an in-depth analysis of the company's financial position.
Valuation is complex, but we're helping make it simple.
Find out whether Teva Pharmaceutical Industries is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:TEVA
Teva Pharmaceutical Industries
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
Undervalued with reasonable growth potential.